AAAAAA

   
Results: 1-7 |
Results: 7
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (vol 12, pg 987, 2001)
Authors: Bertolini, F Mingrone, W Alietti, A Ferrucci, PF Cocorocchio, E Peccatori, F Cinieri, S Mancuso, P Corsini, C Burlini, A Zucca, E Martinelli, G
Citation: F. Bertolini et al., Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. (vol 12, pg 987, 2001), ANN ONCOL, 12(9), 2001, pp. 1333-1333
Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
Authors: Bertolini, F Mingrone, W Alietti, A Ferrucci, PF Cocorocchio, E Peccatori, F Cineri, S Mancuso, P Corsini, C Burlini, A Zucca, E Martinelli, G
Citation: F. Bertolini et al., Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers, ANN ONCOL, 12(7), 2001, pp. 987-990
Evaluation of acute toxicities associated with autologous peripheral bloodprogenitor cell reinfusion in patients undergoing high-dose chemotherapy
Authors: Ferrucci, PF Martinoni, A Cocorocchio, E Civelli, M Cinieri, S Cardinale, D Peccatori, FA Lamantia, G Agazzi, A Corsini, C Tealdo, F Fiorentini, C Cipolla, CM Martinelli, G
Citation: Pf. Ferrucci et al., Evaluation of acute toxicities associated with autologous peripheral bloodprogenitor cell reinfusion in patients undergoing high-dose chemotherapy, BONE MAR TR, 25(2), 2000, pp. 173-177
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma - Reply
Authors: Bertolini, F Paolucci, M Peccatori, F Cinieri, S Agazzi, A Ferrucci, PF Cocorocchio, E Goldhirsch, A Martinelli, G
Citation: F. Bertolini et al., Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma - Reply, BR J HAEM, 108(3), 2000, pp. 662-663
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high dose idarubicin
Authors: Corsini, C Ghielmini, M Mancuso, P Tealdo, F Paolucci, M Zucchetti, M Ferrucci, PF Cocorocchio, E Mezzetti, M Mori, A Riggi, M D'Incalci, M Martinelli, G
Citation: C. Corsini et al., Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high dose idarubicin, BR J CANC, 82(3), 2000, pp. 524-528
Totally implantable central venous access ports for high-dose chemotherapyadministration and autologous stem cell transplantation: analysis of overall and septic complications in 68 cases using a single type of device
Authors: Biffi, R Martinelli, G Pozzi, S Cinieri, S Cocorocchio, E Peccatori, F Ferrucci, PF Pistorio, R Andreoni, B
Citation: R. Biffi et al., Totally implantable central venous access ports for high-dose chemotherapyadministration and autologous stem cell transplantation: analysis of overall and septic complications in 68 cases using a single type of device, BONE MAR TR, 24(1), 1999, pp. 89-93
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
Authors: Bertolini, F Paolucci, M Peccatori, F Cinieri, S Agazzi, A Ferrucci, PF Cocorocchio, E Goldhirsch, A Martinelli, G
Citation: F. Bertolini et al., Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma, BR J HAEM, 106(2), 1999, pp. 504-509
Risultati: 1-7 |